• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Management reaction

Anonymous

Guest
Does anyone know how management is handling the recent large increase in PML cases with Tysabri use?

Heard that several neuros are starting to really balk at continuing their patients on the drug.